文章：

多发性骨髓瘤中的CAR-T细胞疗法：现状及未来挑战

CAR-T cell therapy in Multiple Myeloma: current status and future challenges

原文发布日期：2024-11-26

DOI: 10.1038/s41408-024-01191-8

类型: Review Article

开放获取: 是

英文摘要：

The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the immunosuppressive tumour microenvironment, manufacturing concerns including the potential role of other cellular sources, safety issues such as cytokine release syndrome and neurotoxicity, and optimal patient selection.
 

摘要翻译： 

近年来，多发性骨髓瘤的治疗发生了显著变革，该领域已取得巨大进展。针对B细胞成熟抗原的嵌合抗原受体T细胞疗法，目前已在复发难治性患者中获得广泛批准，并正逐步向更早线治疗推进。本综述将探讨当前监管批准所依据的临床证据，并研究提升CAR-T细胞疗效的潜在机制，包括应对BCMA抗原丢失、利用免疫抑制性肿瘤微环境、优化生产流程（探讨其他细胞来源的潜在作用）、管理细胞因子释放综合征及神经毒性等安全性问题，以及完善患者筛选标准。

原文链接：

CAR-T cell therapy in Multiple Myeloma: current status and future challenges